Company’s 36-month beta value is -0.35.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BMEA is 27.72M, and currently, short sellers hold a 47.75% ratio of that floaft. The average trading volume of BMEA on April 19, 2024 was 1.04M shares.
BMEA) stock’s latest price update
Biomea Fusion Inc (NASDAQ: BMEA) has seen a decline in its stock price by -1.51 in relation to its previous close of 11.16. However, the company has experienced a -15.32% decline in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-07 that There’s a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they’re intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy.
BMEA’s Market Performance
BMEA’s stock has fallen by -15.32% in the past week, with a monthly drop of -30.34% and a quarterly drop of -21.03%. The volatility ratio for the week is 7.87% while the volatility levels for the last 30 days are 7.87% for Biomea Fusion Inc The simple moving average for the last 20 days is -19.26% for BMEA stock, with a simple moving average of -28.23% for the last 200 days.
Analysts’ Opinion of BMEA
Many brokerage firms have already submitted their reports for BMEA stocks, with JP Morgan repeating the rating for BMEA by listing it as a “Neutral.” The predicted price for BMEA in the upcoming period, according to JP Morgan is $14 based on the research report published on April 02, 2024 of the current year 2024.
Truist, on the other hand, stated in their research note that they expect to see BMEA reach a price target of $55. The rating they have provided for BMEA stocks is “Buy” according to the report published on February 06th, 2024.
Scotiabank gave a rating of “Sector Outperform” to BMEA, setting the target price at $41 in the report published on July 27th of the previous year.
BMEA Trading at -29.53% from the 50-Day Moving Average
After a stumble in the market that brought BMEA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.84% of loss for the given period.
Volatility was left at 7.87%, however, over the last 30 days, the volatility rate increased by 7.87%, as shares sank -34.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.25% lower at present.
During the last 5 trading sessions, BMEA fell by -14.54%, which changed the moving average for the period of 200-days by -50.59% in comparison to the 20-day moving average, which settled at $13.32. In addition, Biomea Fusion Inc saw -24.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMEA starting from A2A Pharmaceuticals, Inc., who sale 50,000 shares at the price of $34.56 back on Jun 01 ’23. After this action, A2A Pharmaceuticals, Inc. now owns 3,500,000 shares of Biomea Fusion Inc, valued at $1,728,165 using the latest closing price.
A2A Pharmaceuticals, Inc., the 10% Owner of Biomea Fusion Inc, sale 75,000 shares at $33.81 during a trade that took place back on May 31 ’23, which means that A2A Pharmaceuticals, Inc. is holding 3,550,000 shares at $2,535,750 based on the most recent closing price.
Stock Fundamentals for BMEA
The total capital return value is set at -0.55. Equity return is now at value -84.42, with -71.11 for asset returns.
Based on Biomea Fusion Inc (BMEA), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -7.77. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 52.5.
Currently, EBITDA for the company is -83.63 million with net debt to EBITDA at 1.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.84.
Conclusion
In a nutshell, Biomea Fusion Inc (BMEA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
